Metraipolis › archive › dc_10b60a75f2c7

A Nanobody-LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy — Europe PMC PMID:42080357

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42080357
DOI
10.1002/advs.202523024
License (as archived)
solo-consultazione
Archived
2026-11-02T18:55:21.504Z
SHA-256 of the archived text
76b2fbccda85fb00343fd3790008de8c58f02d96f456303cbe6ffd64a09c1045
Stable URL of this page
https://metraipolis.com/documento/dc_10b60a75f2c7

How to cite

A Nanobody-LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy — Europe PMC PMID:42080357 — Europe PMC (en), https://europepmc.org/article/MED/42080357 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_10b60a75f2c7 (Metraipolis archive dc_10b60a75f2c7, sha256 76b2fbccda85fb00343fd3790008de8c58f02d96f456303cbe6ffd64a09c1045)
BibTeX
@misc{dc10b60a75f2c7,
  title = {A Nanobody-LNP Platform for Targeting and Relicensing Dendritic Cells for Potent Cancer Immunotherapy — Europe PMC PMID:42080357},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42080357},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_10b60a75f2c7; sha256 76b2fbccda85fb00343fd3790008de8c58f02d96f456303cbe6ffd64a09c1045},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42080357. Agents can read the archived copy with the MCP tool read_document.